The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 05, 2025

Filed:

Sep. 11, 2020
Applicant:

Cadila Healthcare Limited, Gujarat, IN;

Inventors:

Rajiv Sharma, Ahmedabad, IN;

Sameer Agarwal, Ahmedabad, IN;

Assignee:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07D 207/08 (2006.01); A61K 31/40 (2006.01); A61K 31/4025 (2006.01); A61K 31/427 (2006.01); A61K 38/20 (2006.01); A61K 38/21 (2006.01); A61K 45/06 (2006.01); A61P 29/00 (2006.01); C07D 207/48 (2006.01); C07D 405/04 (2006.01); C07D 417/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/40 (2013.01); A61K 31/4025 (2013.01); A61K 31/427 (2013.01); A61K 38/2013 (2013.01); A61K 38/21 (2013.01); A61K 45/06 (2013.01); C07D 207/08 (2013.01); C07D 207/48 (2013.01); C07D 405/04 (2013.01); C07D 417/06 (2013.01);
Abstract

The present invention relates to novel heterocyclic compounds of general formula (I) their tautomers, stereoisomers, enantiomers, pharmaceutically acceptable salts and pharmaceutical composition. The compounds of general formula (I) belongs to the family of NOD like receptor family (NLR) protein NLRP3 modulators. The present invention thus relates to novel NLRP3 modulators and use of these novel inhibitor compounds in the treatment of disease or conditions as well as treatment of disease states mediated by NLRP3 as well as treatment of diseases or conditions in which interleukin 1β activity and interleukin-18 (IL-18) is implicated.


Find Patent Forward Citations

Loading…